| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $140.3M | +45.5% |
| SG&A Expense | $38.9M | +16.8% |
| Operating Income | -$179.2M | -38.1% |
| Pre-tax Income | -$174.2M | -39.8% |
| Income Tax | $0 | — |
| Net Income | -$174.3M | -39.8% |
| EPS (Basic) | -$1.99 | +35.0% |
| EPS (Diluted) | -$1.99 | +35.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $59.9M | -25.3% |
| Current Assets | $205.5M | +30.6% |
| Total Assets | $232.5M | +23.3% |
| Current Liabilities | $33.5M | +10.6% |
| Total Liabilities | $52.5M | +2.2% |
| Stockholders' Equity | $180.0M | +31.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$156.3M | -56.3% |
| Capital Expenditures | $1.2M | +76.3% |
| Investing Cash Flow | -$58.5M | -263.4% |
| Financing Cash Flow | $194.4M | +58.8% |
| Free Cash Flow | -$157.4M | -56.4% |